FDA Panel Rejects Merck’s Gefapixant For Chronic Cough, Calls For Better Endpoints

 
• By Brenda Sandburg

Advisory committee votes 12-1 that data do not show the drug provides a meaningful clinical benefit. They suggest other endpoints than 24-hour cough frequency, such as reduction in bouts of coughing.

Coughing woman
Evidence does not support use of Merck's gefapixant for treatment of chronic cough, FDA advisory committee concludes • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers